Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence

Lung Cancer

Volumn 81, Issue 2, 2013, Pages 167-173

  Luo, Hongmei ^a,b   Yount, Caroline ^a   Lang, Hainan ^a   Yang, Aimin ^a   Riemer, Ellen C ^a   Lyons, Katherine ^a   Vanek, Kenneth N ^a   Silvestri, Gerard A ^a   Schulte, Bradley A ^a   Wang, Gavin Y ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF SOUTH CHINA   (China)

Author keywords

Non small cell lung cancer; Nutilin 3a; P53; Radiotherapy; Senescence; SiRNA

Indexed keywords

BETA GALACTOSIDASE; BROXURIDINE; NUTLIN 3; PROTEIN MDM2; PROTEIN P16; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE SILENCING; HUMAN; HUMAN CELL; IRRADIATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION; SENESCENCE;

NON-SMALL CELL LUNG CANCER; NUTILIN-3A; P53; RADIOTHERAPY; SENESCENCE; SIRNA;

APOPTOSIS; CELL AGING; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION, IONIZING; RADIATION-SENSITIZING AGENTS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84879889028     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.04.017     Document Type: Article

References (40)

1. Elmore L.W., Rehder C.W., Di X., McChesney P.A., Jackson-Cook C.K., et al. Adriamycin-induced senescence in breast tumor cells involves functional p53 and telomere dysfunction. J. Biol. Chem. 2002, 277:35509-35515.
2. te Poele R.H., Okorokov A.L., Jardine L., Cummings J., Joel S.P. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002, 62:1876-1883.
3. Rebbaa A., Zheng X., Chou P.M., Mirkin B.L. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene 2003, 22:2805-2811.
4. Chang B.D., Swift M.E., Shen M., Fang J., Broude E.V., Roninson I.B. Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proc. Natl. Acad. Sci. USA 2002, 99:389-394.
5. Yin D.X., Schimke R.T. BCL-2 expression delays drug-induced apoptosis but does not increase clonogenic survival after drug treatment in HeLa cells. Cancer Res. 1995, 55:4922-4928.
6. Suzuki M., Boothman D.A. Stress-induced premature senescence (SIPS) - influence of SIPS on radiotherapy. J. Radiat. Res. 2008, 49(2):105-112.
7. Gewirtz D.A., Holt S.E., Elmore L.W. Accelerated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem. Pharmacol. 2008, 76:947-957.
8. Jones K.R., Elmore L.W., Jackson-Cook C., Demasters G., Povirk L.F., Holt S.E., et al. p53-dependent accelerated senescence induced by ionizing radiation in breast tumor cells. Int. J. Radiat. Biol. 2005, 81:445-458.
9. Schmitt C.A. Cellular senescence and cancer treatment. Biochim. Biophys. Acta 2007, 1775:5-20.
10. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109(3):335-346.
11. Ewald J.A., Desotelle J.A., Wilding G., Jarrard D.F. Therapy-induced senescence in cancer. J. Natl. Cancer Inst. 2010, 102(20):1536-1546.
12. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., et al. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 2005, 436:660-665.
13. Prieur A., Peeper D.S. Cellular senescence in vivo: a barrier to tumorigenesis. Curr. Opin. Cell Biol. 2008, 20:150-155.
14. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., et al. Senescence and tumor clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007, 445(7128):656-660.
15. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445(7128):661-665.
16. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics 2009. CA Cancer J. Clin. 2009, 59(4):225-249.
17. Minna J.D., Roth J.A., Gazdar A.F. Focus on lung cancer. Cancer Cell 2002, 1:49-52.
18. Hall E.J., Wu C.S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int. J. Radiat. Oncol. Biol. Phys. 2003, 56(1):83-88.
19. Brognard J., Clark A.S., Ni Y., Dennis P.A. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001, 61(10):3986-3997.
20. Wang Y., Schulte B.A., Larue A.C., Ogawa M., Zhou D. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 2006, 107:358-366.
21. Wang Y., Scheiber M.N., Neumann C., Calin G.A., Zhou D. MicroRNA regulation of ionizing radiation-induced premature senescence. Int. J. Radiat. Oncol. Biol. Phys. 2011, 81:839-848.
22. 2-induced senescent phenotype and cell cycle arrest in normal human diploid fibroblasts. Exp. Cell Res. 2004, 298:188-196.
23. Dittmann K., Mayer C., Rodemann H.P. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother. Oncol. 2005, 76:157-161.
24. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 1995, 92:9363-9367.
25. Krishnamurthy J., Torrice C., Ramsey M.R., Kovalev G.I., Al-Regaiey K., Su L., et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 2004, 114:1299-1307.
26. Meng A., Wang Y., Van Zant G., Zhou D. Ionizing radiation and busulfan induce premature senescence in murine bone marrow hematopoietic cells. Cancer Res. 2003, 63:5414-5419.
27. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999, 285:1733-1737.
28. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253(5015):49-53.
29. Mori S., Ito G., Usami N., Yoshioka H., Ueda Y., Kodama Y., et al. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma. Cancer 2004, 100:1673-1682.
30. Lai S.L., Perng R.P., Hwang J. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J. Biomed. Sci. 2000, 7(1):64-70.
31. Chen F., Wang W., El-Deiry W.S. Current strategies to target p53 in cancer. Biochem. Pharmacol. 2010, 80:724-730.
32. Lin R.K., Wu C.Y., Chang J.W., Juan L.J., Hsu H.S., Chen C.Y., et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res. 2010, 70(14):5807-5817.
33. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303(5659):844-848.
34. Sibley G.S., Jamieson T.A., Marks L.B., Anscher M.S., Prosnitz L.R. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40(1):149-154.
35. Park S.Y., Kim Y.M., Pyo H. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated. Mol. Cancer 2010, 9:222.
36. Sura S., Yorke E., Jackson A., Rosenzweig K.E. High-dose radiotherapy for the treatment of inoperable non-small cell lung cancer. Cancer J. 2007, 13(4):238-242.
37. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387(6630):296-299.
38. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L., Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358(6381):80-83.
39. Muthusamy V., Hobbs C., Nogueira C., Cordon-Cardo C., McKee P.H., Chin L., et al. Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes Cancer 2006, 5(5):447-454.
40. Arya A.K., El-Fert A., Devling T., Eccles R.M., Aslam M.A., Rubbi C.P., et al. Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53. Br. J. Cancer 2010, 103(2):186-195.